Impact News +++ Palantir stock plummets 20% from highs in longest losing streak since April 2024 (CNBC) +++ PALANTIR Aktie +3,58%

WARSAW STOCK EXCHANGE Aktie

>Performance

1 Woche: -2,5%

1 Monat: +16,6%

3 Monate: +14,5%

6 Monate: +35,4%

1 Jahr: +40,7%

laufendes Jahr: +41,6%

>WARSAW STOCK EXCHANGE Aktie

Name:

WARSAW STOCK EXCHANGE

Land:

Polen

Sektor:

Finanzen

ISIN/ Wkn:

PLGPW0000017 / A1C7YU

Symbol/ Ticker:

WSX (Frankfurt)

Kürzel:

FRA:WSX, ETR:WSX, WSX:GR

Index:

Webseite:

https://www.gpw.pl/

Profil:

The Warsaw Stock Exchange is a leading financial e..
>Volltext..

Marktkapitalisierung:

561.87 Mio. EUR

Unternehmenswert:

462 Mio. EUR

Umsatz:

106.65 Mio. EUR

EBITDA:

32.7 Mio. EUR

Nettogewinn:

38.03 Mio. EUR

Gewinn je Aktie:

0.91 EUR

Schulden:

5.96 Mio. EUR

Liquide Mittel:

33.84 Mio. EUR

Operativer Cashflow:

38.15 Mio. EUR

Bargeldquote:

2.33

Umsatzwachstum:

8.28%

Gewinnwachstum:

12.71%

Dividende je Aktie:

0.74 EUR

Dividendenrendite:

5.54%

Dividendenschätzung:

5.52%

Div. Historie:

22.07.25 - 0.741321€
23.07.24 - 0.71423995€

>weitere anzeigen...

Insiderhandel:

Suchwörter:

WARSAW STOCK EXCHANGE

Letzte Datenerhebung:

20.08.25

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 41.97 Mio. St.

Frei handelbar: 64.99%

Leerverk. Aktien: -

Rückkaufquote: -

Mitarbeiter: 569

Umsatz/Mitarb.: 0.17 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: -7.01%

Bewertung:

KGV: 14.13

KGV lG: 12.67

KUV: 4.91

KBV: 2.18

PEG-Ratio: 1.39

EV/EBITDA: 14.13

Rentabilität:

Bruttomarge: 47.2%

Gewinnmarge: 35.66%

Operative Marge: 23.9%

Managementeffizenz:

Gesamtkaprendite: 12.39%

Eigenkaprendite: 15.75%

>Peer Group

Es sind 26 Aktien bekannt.

>Chart & Kurs - Stuttgart

>Alle News

21.07.25 - 23:39	XFRA: DIVIDEND/INTEREST INFORMATION - 22.07.2025 - EQUBF_01 (XETRA)
	Das Instrument WSX PLGPW0000017 WARSAW STOCK EXCH. ZY1 EQUITY wird ex Dividende/Zinsen gehandelt am 22.07.2025 The instrument WSX PLGPW0000017 WARSAW STOCK EXCH. ZY1 EQUITY has its ex-dividend/interest day on 22.07.2025...

20.07.25 - 21:30	XFRA: DIVIDEND/INTEREST INFORMATION - 22.07.2025 - EQUBF_01 (XETRA)
	Das Instrument WSX PLGPW0000017 WARSAW STOCK EXCH. ZY1 EQUITY wird cum Dividende/Zinsen gehandelt am 21.07.2025 und ex Dividende/Zinsen am 22.07.2025 The instrument WSX PLGPW0000017 WARSAW STOCK EXCH. ZY1 EQUITY has its pre-dividend/interest day on 21.07.2025 and its ex-dividend/interest day on 22.07.2025...

22.05.25 - 10:01	Poland′s WIG index climbs 28.6% in 2025 on Ukraine peace hopes and economic stability (IntelliNews)
	The Warsaw Stock Exchange's (WSE) benchmark WIG index has gained 28.6% since the beginning of 2025, outperforming major global markets amid investor optimism over a potential peace settlement in Ukraine....

08.04.25 - 03:48	Warsaw Stock Exchange halts trading as global markets tumble (IntelliNews)
	Trading on the Warsaw Stock Exchange was suspended for one hour on the afternoon of April 7, the exchange's operator said, citing concerns about market stability....

07.04.25 - 16:01	Warsaw Bourse Suspends Trade Due to Volatility, High Volumes (Bloomberg)
	The Warsaw Stock Exchange is suspending trade on all its markets for more than an hour on Monday, citing “safety reasons” amid a spike in volatility and volumes....

26.03.25 - 08:01	Warsaw Stock Exchange′s core profit rises on record revenue growth (Reuters EN)
	Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

02.10.24 - 11:03	Poland′s Zabka convenience store chain aims to raise €1.5bn in upcoming Warsaw IPO (IntelliNews)
	IPO looks set to be the Warsaw Stock Exchange's largest listing in four years and among the top five European IPOs in 2024 to date....

26.09.24 - 07:03

PolTREG starts preclinical CAR-Treg development for neuroinflammatory autoimmune diseases (GlobeNewswire EN)

Gdańsk, Poland – 26 September 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases, today announces it has launched a study with CAR-Treg cells in a humanized mouse model of neuroinflammatory disease. Data from the study are anticipated by March 30, 2025, and will help determine the pathway to clinical evaluation. The study will measure safety and efficacy of the CAR-Treg cell therapy, which will be administered systemically as well as intrathecally. PolTREG's CAR-Treg cells are manufactured using the same technology platform as its lead product PTG-007, a polyclonal Treg cell therapy, for which PolTREG has gathered over a decade of clinical safety and efficacy data, largely in type-1 diabetes (T1D) patients....

16.09.24 - 07:06

China patent notification boosts PolTREG′s development of Treg cell therapy in multiple sclerosis (GlobeNewswire EN)

Gdańsk, Poland – 16 September 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG) , a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases, today announces that China's National Intellectual Property Administration, PRC (CNIPA) has issued a notification to grant a patent for the intrathecal administration of the company's cellular therapies in patients with multiple sclerosis (MS). The intrathecal administration is an established method used to deliver a therapy across the blood-brain barrier via injection into the subarachnoid space....

09.09.24 - 07:03

PolTREG Treg cell therapy for patients with type-1 diabetes shows long-term clinical remission and insulin independence (GlobeNewswire EN)

Gdańsk, Poland – 9 September 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG) , a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases, today announces data showing that treatment with its Treg cell therapy, PTG-007, resulted in clinical remission for up to 12 years in patients with type-1 diabetes (T1D). A subset of these patients remained insulin-independent up to 18 to 24 months after treatment. The company will present the data at the INNODIA EASD symposium in Madrid today....

22.07.24 - 23:51	XFRA : DIVIDEND/INTEREST INFORMATION - 23.07.2024 - PLGPW0000017 (XETRA)
	Das Instrument WSX PLGPW0000017 WARSAW STOCK EXCH. ZY1 EQUITY wird ex Dividende/Zinsen gehandelt am 23.07.2024 The instrument WSX PLGPW0000017 WARSAW STOCK EXCH. ZY1 EQUITY has its ex-dividend/interest day on 23.07.2024...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Am Anfang war die Kraft. - Paula Modersohn-Becker

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram